Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2023.03.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI.
Urol Oncol
December 2024
Department of Urology, Yale School of Medicine, New Haven, CT; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT; Yale Cancer Outcomes, Public Policy and Effectiveness Research Center, New Haven, CT. Electronic address:
Background And Objective: As most Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions on MRI harbor Gleason grade (GG) group ≥2 disease on biopsy, optimal management of patients with imaging-biopsy discordance remains unclear. To estimate grade misclassification, we evaluated the incidence of Gleason upgrading among patients with GG1 disease in the setting of a PI-RADS 5 lesion.
Methods: We conducted a single-institution retrospective analysis to identify patients with GG1 prostate cancer on fusion biopsy with MRI demonstrating ≥1 PI-RADS 5 lesion.
Management strategies for radio-recurrent prostate cancer: a comprehensive review.
Transl Cancer Res
November 2024
Department of Urology, Yale School of Medicine, New Haven, CT, USA.
Radiation- (radio-)recurrent prostate cancer poses a significant challenge in clinical management due to its complexity and varied treatment responses. The recurrence of prostate cancer following radiotherapy necessitates a nuanced management strategy that considers disease stage and aggressiveness, patient health status, and prior treatment modalities. Androgen deprivation therapy (ADT), a cornerstone in the management of regional or distant relapse, often initiates the therapeutic cascade, effectively suppressing tumor growth by targeting androgen signaling.
View Article and Find Full Text PDFEditorial Comment on "Commercial Prices and Care for Medicare Beneficiaries With Prostate Cancer.
Urology
December 2024
Yale School of Medicine, New Haven, CT. Electronic address:
Prostate cancer in people with HIV.
Curr Opin Infect Dis
February 2025
Department of Urology, Yale School of Medicine, New Haven, Connecticut, USA.
Article Synopsis
- Prostate cancer is becoming more prevalent among people living with HIV (PWH), yet research on this intersection is limited.
- Current evidence suggests that prostate cancer might now be the most common cancer among U.S. PWH, with tumor characteristics not varying significantly by HIV status.
- There is ongoing debate about optimal screening methods for prostate cancer in PWH, and while outcomes may have improved in recent years, treatment tolerance remains a critical concern that needs further study.
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020.
JAMA
December 2024
Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!